Radon-222 Brain Dosimetry.
| Autor: | Harley NH; Naomi H. Harley, New York University School of Medicine, Department of Environmental Medicine, Marine View Plaza, Apt. 24E, Hoboken, NJ 07030., Robbins ES; Edith S. Robbins, New York University School of Medicine, Department of Cell Biology, easr@optonline.net (retired). |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Health physics [Health Phys] 2022 May 01; Vol. 122 (5), pp. 575-578. |
| DOI: | 10.1097/HP.0000000000001533 |
| Abstrakt: | Abstract: The human brain dose from radon-222 (222Rn) exposure is calculated here using 222Rn tissue solubility data. A fraction of 222Rn inhaled dissolves in blood and cellular fluids and circulates to brain and all organs. Radon-222 has a relatively high solubility in blood and body fluids based on human inhalation experiments. The brain dose uses calculated concentrations of 222Rn in blood and cellular fluids from exhaled breath measurements following human exposure in a 222Rn chamber. The annual brain dose from continuous inhalation of a concentration of 100 Bq m-3 is about 450 times less than the dose to bronchial epithelium from inhalation of the same 222Rn concentration. Based on the 222Rn dosimetry here, it is highly unlikely that brain cancer is related to even high 222Rn exposures. Any functional or neurodegenerative issues from exposure to very small doses of 222Rn alpha particles are, at present, unknown. Competing Interests: The authors declare no conflicts of interest. (Copyright © 2022 Health Physics Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|